Pharmaceutical composition containing crisdesalazine with improved stability and dissolution rate

The use of surfactants with an HLB value of 8 or higher and specific excipients in the Crisdesalazine composition addresses the solubility and stability challenges, enhancing bioavailability and stability, effectively addressing the pH-dependent solubility issues and improving therapeutic outcomes for Crisdesalazine.

WO2024248510A1PCT designated stage expired Publication Date: 2024-12-05GNT PHARMA CO LTD
View PDF 11 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2024/007420
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-06-02
Filing Date
2024-05-31
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Crisdesalazine, a poorly soluble drug, faces challenges in achieving both stability and dissolution rate due to its pH-dependent solubility, with low solubility in acidic pH and high solubility in alkaline pH, making it difficult to maintain effective absorption in the gastrointestinal tract and stability in oral pharmaceutical formulations.

Method used

A pharmaceutical composition incorporating Crisdesalazine with anionic or nonionic surfactants having a Hydrophilic and Lipophilic Balance (HLB) value of 8 or higher, such as sodium lauryl sulfate and polyethylene glycol-15-hydroxystearate, to enhance solubility and bioavailability, while maintaining the pH below 7 to ensure stability, using mannitol and microcrystalline cellulose as diluents and excluding alkaline excipients.

Benefits of technology

The composition significantly improves the dissolution rate and stability of Crisdesalazine, ensuring better bioavailability and long-term stability, even under accelerated conditions, by optimizing solubility and pH management, thus enhancing its therapeutic effectiveness for neurodegenerative and inflammatory diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2024007420_05122024_PF_FP_ABST
    Figure KR2024007420_05122024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to a pharmaceutical composition comprising crisdesalazine or a salt thereof, which has improved stability by reducing the content of related substances of crisdesalazine, and has an increased dissolution rate by improving the intrinsic solubility thereof. The composition of the present invention secures stability and bioavailability, and thus is more effective in treating neurodegenerative diseases (Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, epilepsy accompanied by free radical neurotoxicity, cerebral trauma, spinal injury, and the like), inflammatory diseases (gastritis, colitis, pancreatitis, arthritis, diabetic inflammation, inflammatory bowel disease, nephritis, hepatitis, arteriosclerosis inflammation, and the like), stress disorders (anxiety disorder, depression, and the like), and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Pharmaceutical composition containing crisdesalazine with improved stability and dissolution rate

[0001] This application claims priority to Korean Patent Application No. 10-2023-0071943, filed June 2, 2023, the entire disclosure of which is incorporated herein by reference.

[0002] The present invention relates to a pharmaceutical or pharmaceutical composition comprising crisdesalazine or a pharmaceutically acceptable salt thereof as an active ingredient, and particularly to a pharmaceutical composition having improved stability, dissolution rate, bioavailability, etc.

[0003] Crisdesalazine (2-hydroxy-5-[2-(4-trifluoromethylphenyl)ethylamino] benzoic acid) acts as an antioxidant and anti-inflammatory agent through selective inhibition of microsomal prostaglandin E2 synthase (mPGES-1), the terminal enzyme in the prostaglandin E2 (PGE2) pathway induced by proinflammatory cytokines. In addition, Crisdesalazine is known to be effective in the treatment of various neurodegenerative diseases, inflammatory diseases, and psychiatric disorders.

[0004] PCT Patent Publication WO 01 / 79153 A1 provides a pharmaceutical composition comprising Crisdesalazine or a salt thereof for protecting the central nervous system from acute or chronic damage to the central nervous system, and also for treating NMDA (N-methyl-D-aspartate) neurotoxicity, Zn, by administering a therapeutically effective amount thereof to a patient or animal suffering from acute or chronic damage to the central nervous system. 2+Provided are methods for treating or preventing neurological diseases associated with neurotoxicity or oxidative stress. Specifically, Crisdesalazine or a salt thereof is reported to have a protective function against central nervous system damage caused by ischemic nerve damage (ischemia), hypoxia, hypoglycemia, traumatic brain injury, traumatic spinal cord injury, epilepsy, Huntington's disease, Parkinson's disease, Alzheimer's disease, or amyotrophic lateral sclerosis.

[0005] PCT Patent Publication WO 2007 / 119973 and US Patent 8455470B2 disclose that Crisdesalazine or a salt thereof is effective for one or more inflammatory diseases selected from the group consisting of gastritis, colitis, pancreatitis, arthritis, diabetic inflammation, inflammatory bowel disease, nephritis, hepatitis, and inflammation in arteriosclerosis, and PCT Patent Publication WO2010-090494 A2 discloses that Crisdesalazine or a salt thereof is effective for the treatment or prevention of stress disorder, anxiety disorder, or depression.

[0006] As confirmed by the inventors through experiments, crisdesalazine is a very poorly soluble drug, with low solubility under acidic pH conditions and high solubility under alkaline pH conditions. If a formulation is manufactured without considering these physicochemical properties, the drug will not dissolve in the gastrointestinal tract after oral administration, resulting in low absorption rates, making it difficult to achieve an effective therapeutic effect. Furthermore, incorporating an alkaline component into the formulation to enhance solubility may adversely affect the stability of crisdesalazine. Therefore, it is problematic to obtain a formulation that satisfies both stability and dissolution rates for crisdesalazine.

[0007] Therefore, the problem to be solved by the present invention is to provide a pharmaceutical composition having improved dissolution rate of Crisdesalazine or a pharmaceutically acceptable salt thereof, a poorly water-soluble drug, while also improving stability. In other words, the present invention aims to provide an oral pharmaceutical formulation in which Crisdesalazine, which is poorly water-soluble, is improved to have better solubility and absorbability in the gastrointestinal tract, and at the same time, to provide a pharmaceutical product in which the long-term stability of the formulation, particularly the long-term stability of the related substances, is secured.

[0008] First, the inventors of the present invention measured the pH-dependent equilibrium solubility of Crisdesalazine (2-hydroxy-5-[2-(4-trifluoromethylphenyl) ethylamino] benzoic acid), and the results of the solubility at 12 and 24 hours are as shown in Table 1 and Figure 1 below. As shown in the table below, the equilibrium solubility of Crisdesalazine in purified water was very low at pH 7 or lower (38.2 μg / mL or less at 12 hours and 39.7 μg / mL or less at 24 hours), but the solubility increased significantly at pH 8 (253.9 μg / mL at 12 hours and 251.6 μg / mL at 24 hours), and showed a greater pH-dependent increase at higher pHs.

[0009]

[0010] As shown in the results in the table above and Figure 1, solubility increases at high pH, ​​and thus, it was thought that using an alkalizing agent could increase solubility and bioavailability. However, an increase in the pH within the composition had negative effects on stability, and as a result, achieving both stability and dissolution rate was not easy.

[0011] That is, in order to achieve the two objectives of stability and dissolution rate (bioavailability), one aspect of the present invention provides a pharmaceutical composition comprising Crisdesalazine or a pharmaceutically acceptable salt thereof as an active ingredient and a surfactant having an HLB (Hydrophilic and Lipophilic Balance) value of 8 or higher.

[0012]

[0013] The present inventors evaluated various additives, and among them, anionic surfactants and nonionic surfactants with an HLB value of 8 or higher were the most preferable. Cationic surfactants are not much different from the solubility of crisdesalazine itself in their solubilizing ability, and when contained together with crisdesalazine in the formulation, the amount of related substances, which are impurities, increases under accelerated conditions, making them unsuitable as solubilizing agents. In addition, nonionic surfactants with an HLB value of less than 8 showed little effect in improving drug solubility even in aqueous solutions containing 10% or more. On the other hand, when anionic surfactants or nonionic surfactants with an HLB value of 8 or higher were included, the solubility improved by more than two times, resulting in an increase in the dissolution rate of the formulation.

[0014] Crisdesalazine or its salt has the function of protecting the central nervous system damage causing ischemic nerve damage, hypoxia, hypoglycemia, brain trauma, spinal trauma, epilepsy, Huntington's disease, Parkinson's disease, Alzheimer's disease or amyotrophic lateral sclerosis. It is preferable that the content of these in the dosage form contain 10-500 mg, and more preferably 50-200 mg. However, in the case of preparations exceeding 200 mg, the size of the dosage form may be large and inconvenient to take, but when this surfactant is used, it is possible to produce a dosage form of a size suitable for taking even in a high-content Crisdesalazine preparation of 200 mg or more.

[0015] As anionic surfactants used, it is preferable to use, for example, sodium lauryl sulfate, sodium dodecyl sulfate, etc. As nonionic surfactants of the present invention, surfactants commonly used in the pharmaceutical field having an HLB value of 8 or higher can be used. For example, polyethylene glycol-15-hydroxystearate (e.g., solutol) TM HS 15), polyoxyethylene glycol, natural or hydrogenated castor oil (e.g., Cremophor TM RH 40, Cremophor TM RH 60), polyoxyethylene-polyoxypropylene copolymers (e.g., poloxamers) TM 407, Poloxamer TM 118), sucrose fatty acid ester (e.g., RyotoSugar Ester TM S-1570, S-1670, P-1570, P-1670, L-1695), synthetic vitamin E derivatives (e.g., vitamin E TPGS) TM ), sorbitan esters (e.g., sorbitan monolaurate) and polyoxyethylene sorbitan fatty acid esters (e.g., polysorbate TM 80, polysorbate TM 20, polysorbate TM40), fatty acid macrogol glycerides (e.g. Gelucire 44 / 14 TM ), polyglyceryl fatty acid esters (e.g. Almax-9420, Almax-9640, Plurol oleique MB), lecithin, caprylcaproyl polyoxy-8-glycerides (e.g. Labrasol TM ), sorbitan fatty acid esters (e.g., sorbitan laurate), etc. can be used.

[0016] In a preferred embodiment of the present invention, the surfactant used together with Crisdesalzine according to the present invention is sodium lauryl sulfate, which is an anionic surfactant. In a preferred embodiment of the present invention, the surfactant used together with Crisdesalzine according to the present invention is polyethylene glycol-15-hydroxystearate, polyoxyethylene glycol-glycolized natural or hydrogenated castor oil, sucrose fatty acid ester (e.g., RyotoSugar Ester). TM S-1570, S-1670, P-1570, P-1670, L-1695), polyoxyethylene-polyoxypropylene copolymers, synthetic vitamin E derivatives (e.g., vitamin E TPGS) TM ), or a surfactant having an HLB value of 8 or higher among polyoxyethylene sorbitan fatty acid esters (e.g., polysorbate 80). In a more preferred embodiment of the present invention, the surfactant used together with Crisdesalzine according to the present invention is sodium lauryl sulfate, polmoxamer-407, or a mixture thereof.

[0017] It is preferable to use the surfactant in an amount of 0.1-10 wt% based on the total weight of the entire composition, and more preferably, it is preferable to include an amount of 0.5-5 wt%.

[0018]

[0019] As used herein, "pharmaceutically acceptable salt" means a salt formed with a non-toxic or substantially non-toxic acid or base. Pharmaceutically acceptable salts include, but are not limited to, salts prepared with lithium, sodium, potassium, calcium, ammonium, magnesium, or organic amino acids (e.g., diethylamine).

[0020]

[0021] One aspect of the present invention provides a pharmaceutical composition substantially free of lactose. The inventors of the present invention conducted experiments to evaluate the "compatibility" of Crisdesalzine with various excipients, and the results showed that compatibility with calcium phosphate dibasic, hydroxypropyl methylcellulose (HPMC), meglumine, and magnesium oxide (MgO) was poor.

[0022] In an actual 13-week compatibility study, lactose was judged to be suitable for mixing as it showed little change in flexible substances except for some powder coagulation. However, it was found to be undesirable in a long-term stability test of an actual formulation for more than 1-2 years. In other words, the long-term stability of mixing crisdesalzine and lactose was difficult to predict based only on a short-term compatibility evaluation test. Therefore, it is preferable that the composition according to the present invention substantially does not contain lactose, dibasic calcium phosphate, HPMC, meglumine, MgO, etc., and it is particularly preferable that it substantially does not contain lactose.

[0023] In the present invention, “substantially free of” means that it is contained in an amount of 2 wt% or less based on the total weight of the composition, preferably in an amount of 1 wt% or less, more preferably in an amount of 0.5 wt% or less, and most preferably in an amount of not contained at all.

[0024] Another aspect of the present invention also provides a pharmaceutical composition comprising mannitol, microcrystalline cellulose or a mixture thereof as a diluent instead of lactose.

[0025] "Diluent" means an inert substance used as a filter to create desirable bulk, flow properties, and compression characteristics in the manufacture of a solid dosage form. Examples thereof include mannitol, maltitol, isomalt, sucrose, lactose, colloidal silicon dioxide, dextrin, dextrates, microcrystalline cellulose, crystalline cellulose, glucose, polydextrose, starch, pregelatinized starch, corn starch, potato starch, cellulactose, anhydrous lactose, and mixtures thereof. The present inventors have determined that among these various diluents, mannitol and / or microcrystalline cellulose are preferred. Accordingly, one aspect of the present invention provides a composition comprising mannitol or microcrystalline cellulose as a diluent. Another preferred aspect of the present invention provides a composition comprising both mannitol and microcrystalline cellulose as diluents. In the present invention, D-mannitol can be used as the mannitol, and for example, 100SD and / or 200SD can be used.

[0026] The content of such mannitol and / or microcrystalline cellulose may be included in an amount of 5-80 wt% based on the total weight of the composition, and is preferably included in an amount of 10-60 wt%.

[0027] One aspect of the present invention provides a pharmaceutical composition comprising 5-70 wt% of Crisdesalazine or a pharmaceutically acceptable salt thereof, 5-80 wt% of mannitol, 5-80 wt% of microcrystalline cellulose, 2-10 wt% of a disintegrant, 0.1-10 wt% of sodium lauryl sulfate, and 0.1-10 wt% of a lubricant, based on the total weight of the composition, and preferably a pharmaceutical composition in the form of a tablet comprising 5-50 wt% of Crisdesalazine or a pharmaceutically acceptable salt thereof, 10-60 wt% of mannitol, 10-60 wt% of microcrystalline cellulose, 2-10 wt% of a disintegrant, 0.5-5 wt% of sodium lauryl sulfate, and 0.5-5 wt% of a lubricant, based on the total weight of the composition.

[0028] In the composition of the present invention, disintegrants that may be used include carboxymethylcellulose calcium (CMC-Ca), crospovidone, sodium starch glycolate, croscarmellose sodium, and low-substituted hydroxypropyl cellulose. In a preferred embodiment of the present invention, the disintegrant is croscarmellose sodium.

[0029] In the composition of the present invention, the lubricant may be colloidal silica, magnesium stearate, stearic acid, talc, or sodium stearyl fumarate, talc, sodium stearyl fumarate, or Ryoto TM ester), hydrogenated castor oil, etc. may be used. In a preferred embodiment of the present invention, the lubricant is sodium stearyl fumarate. The content of the lubricant may be 0.1-5 wt% based on the total weight of the composition.

[0030] The composition of the present invention is in the form of tablets, and these tablets can be coated with a coating material well known to those skilled in the art to which the present invention pertains. Commercially available coating products can be used as such coating materials. For example, the coating may be Opadry® from Colorcon. ®) 03B62519, 03B59005, 85F530135, 85F220008, etc. can be used, and these can be used alone, mixed and used as a coating material, or used in a sequential coating manner. For example, the tablet of the present invention is a double-coated tablet that is sealed-coated after sub-coating.

[0031] In a preferred embodiment of the present invention, the preferred maximum range of use of Crisdesalazine and excipients (but not limited to the substances listed below) is as shown in Table 2 below.

[0032]

[0033] One aspect of the present invention also provides a pharmaceutical composition comprising Crisdesalazine or a pharmaceutically acceptable salt thereof as an active ingredient, the composition having a pH of less than 7 when dispersed in 250 mL of purified water.

[0034]

[0035] Considering the expected human therapeutic dose of crisdesalazine, the maximum (individual) related substance (MRS) should be less than 0.2% according to the ICH Q3B(R2) guideline. When formulating a formulation using excipients with an alkaline pH, the formation of related substances, which are impurities, increases and the stability of the drug within the formulation decreases. To overcome this problem, the formulation can be manufactured by excluding excipients and additives that exhibit alkaline properties. In other words, the stability of the formulation can be maintained by maintaining the pH of the formulation below 7.

[0036] Accordingly, one aspect of the present invention provides a pharmaceutical composition containing Crisdesalazine or a pharmaceutically acceptable salt thereof, which substantially does not contain additives exhibiting alkaline properties, such as sodium carbonate, sodium bicarbonate, sodium hydroxide, potassium hydroxide, magnesium hydroxide, magnesium carbonate, calcium phosphate, sodium phosphate, dicalcium phosphate, magnesium trisilicate, etc.

[0037] In order to maintain the pH of the formulation below 7, the present invention provides a pharmaceutical composition comprising (i) Crisdesalazine or a pharmaceutically acceptable salt thereof and (ii) an acidifying agent, and further comprising (iii) a surfactant having an HLB of 8 or higher to secure the dissolution rate of the Crisdesalazine component, which is poorly soluble in water. The surfactant having an HLB of 8 or higher may be an anionic surfactant and / or a nonionic surfactant, and these are as described above.

[0038] Examples of the acidifying agent include propionic acid, isobutylic acid, oxalic acid, malic acid, malonic acid, benzoic acid, succinic acid, suberic acid, fumaric acid, mandelic acid, phthalic acid, benzenesulfonic acid, p-tolylsulfonic acid, citric acid, tartaric acid, methanesulfonic acid, hydrochloric acid, bromic acid, nitric acid, carbonic acid, monohydrogen-carbonic acid, phosphoric acid, monohydrogen-phosphoric acid. Dihydrogen-phosphoric acid, sulfuric acid, monohydrogen-sulfuric acid, hydrogen iodide, phosphorous acid, glucuronic acid, galactunoric acid, etc. can be used. In a preferred embodiment of the present invention, the acidifying agent is fumaric acid, succinic acid, tartaric acid, oxalic acid, or a mixture thereof.

[0039]

[0040] In addition to the aforementioned ingredients, the composition of the present invention may further contain additional binders, disintegrants, lubricants, dispersants, etc. suited to the formulation characteristics (within the scope that does not impede the purpose of the present invention), and may be provided in a form formulated as an oral preparation such as a tablet, capsule, granule, powder, etc. Among these, the most preferred formulations are tablets and capsules. These formulations may be manufactured according to methods commonly used in the pharmaceutical field. For example, the composition may be manufactured in various ways using conventional tablet or capsule manufacturing methods such as direct mixing method, wet granulation method, and dry granulation method, and there is no particular limitation on the manufacturing method.

[0041] In the present invention, the term "binder" refers to a substance capable of imparting elasticity and adhesiveness to the formed formulation, particularly to increase the strength of the tablet. Examples of the binder include, but are not limited to, polyvinylpyrrolidone (PVP), sodium carboxymethylcellulose (CMC-Na), starch paste, gelatin, hydroxymethylcellulose, xanthan gum, gum arabic, and hydroxypropyl cellulose (HPC).

[0042]

[0043] The pharmaceutical composition according to the present invention can be used for the treatment, improvement or prevention of neurodegenerative diseases (Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, epilepsy accompanied by free radical neurotoxicity, brain trauma and spinal cord injury, etc.), inflammatory diseases (gastritis, colitis, pancreatitis, arthritis, diabetic inflammation, inflammatory bowel disease, nephritis, hepatitis, arteriosclerotic inflammation, etc.), stress disorders (anxiety disorder, depression, etc.), etc., but the present invention is not limited to such uses.

[0044] The present invention provides a pharmaceutical composition comprising Crisdesalazine or a pharmaceutically acceptable salt thereof as an active ingredient, which has secured stability and a good dissolution rate, thereby ensuring bioavailability.

[0045] Figure 1 shows the results of a pH-dependent equilibrium solubility experiment of Crisdesalazine in a buffer solution at 1 hour and 12 hours.

[0046] Figure 2 shows the results of a 120-minute dissolution rate evaluation of Examples 4-7 according to the present invention. A sodium borate buffer solution with a pH of 8.6 was used as the dissolution medium.

[0047] Hereinafter, the present invention will be described in detail, using examples and the like, to aid understanding. However, the examples according to the present invention may be modified in various different forms, and the scope of the present invention should not be construed as being limited to the following examples. The examples of the present invention are provided to more fully explain the present invention to those of average skill in the art.

[0048]

[0049] Preparation of Example 1-3

[0050] Tablets containing crisdesalazine as the main ingredient were manufactured as follows according to the composition shown in the table below. Specifically, crisdesalazine, croscarmellose sodium, and sodium lauryl sulfate were mixed, sieved (using 20 mesh), and then microcrystalline cellulose and D-mannitol were mixed. A lubricant (sodium stearyl fumarate) sieved through 40 mesh was mixed into this mixture, and then compressed into round tablets using a rotary tablet press. Afterwards, film coating was performed using Opadry.

[0051] Dose-proportional pharmaceutical composition of 2-hydroxy-5-[2-(4-trifluoromethylphenyl)ethylamino]benzoic acid (Crisdesalazine)

[0052]

[0053]

[0054] Evaluation of hardness, wear resistance, etc. of Example 1-3

[0055] The tablets manufactured in the above examples 1-3 were evaluated and the results are shown in the table below.

[0056]

[0057] As shown in the results in the table above, tablets with good hardness, friability, etc. could be manufactured according to the prescription of Examples 1-3.

[0058]

[0059] Long-term stability evaluation of Examples 1 and 2

[0060] After manufacturing tablets by scale-up using the same recipe as in Examples 1 and 2 above, long-term stability was evaluated under the conditions of 25±2℃, 60±5% RH (Relative Humidity), and the results are shown in the tables below.

[0061]

[0062]

[0063] RRT: Relative retention time

[0064] The above stability study data confirms the stability of the composition according to the present invention in long-term stability evaluations. Each flexible substance (the maximum value of the known flexible substance, the unknown flexible substance, and the total flexible substance) remained within the standards throughout the test period. In other words, the composition according to the present invention was confirmed to be able to maintain improved stability and dissolution rate for an extended period.

[0065] For reference, as shown in the aforementioned Figure 1, it was observed that the equilibrium solubility increased between pH 8 and 9 and was maintained for up to 12 hours, and thus a dissolution test was performed to study the release profile.

[0066] The dissolution test was performed using borate buffer pH 8.6 (900 mL) as a medium, according to the second method of the Korean Pharmacopoeia Dissolution Test Method, and the rotation speed was 75 rpm. The amount of dissolution was evaluated at 0, 10, 15, 30, 60, 90, and 120 minutes after the start of the test. As an analysis method, the absorbance of the standard solution and test solution was measured at a wavelength of 336 nm according to the ultraviolet-visible absorbance measurement method in the general test methods of the Korean Pharmacopoeia.

[0067]

[0068] Accelerated stability evaluation of Example 2

[0069] After manufacturing tablets by scaling up using the same recipe as in Example 2, the stability was evaluated under the conditions of 40±2℃ and 75±5% RH, and the results are shown in the table below.

[0070]

[0071] RRT: Relative retention time, BLOD: Below detection limit [Below of LOD (Limit of Detection), LOD=0.025%], BLOQ: Below quantitation limit [Below of LOQ (Limit of Quantitation), LOQ=0.08%].

[0072] In all three batches manufactured and evaluated, the composition according to the present invention was confirmed to be stable for a sufficient period of time under accelerated conditions. That is, it was confirmed that the composition according to the present invention can maintain improved stability and dissolution rate even after storage under accelerated conditions.

[0073]

[0074] Preparation of Example 4-7 and Comparison 1-4

[0075] Tablets containing the active ingredient Crisdesalazine were manufactured with the composition shown in the table below. Except for film coating, they were manufactured in a similar manner to Example 1. For Comparative Examples 1, 2, 3, and 4, the ingredients included in the capsule formulation were simply mixed and then filled into empty capsules.

[0076]

[0077]

[0078] Evaluation of dissolution rates of Example 4-7 and Comparative Example 1-4

[0079] The dissolution rates of the formulations prepared in Example 4-7 (tablets) and Comparative Example 1-4 (capsules) were evaluated, and the dissolution rate results, along with the HLB values ​​of the solubilizers, are shown in the table below. In addition, the 120-minute dissolution rate evaluation results of Example 4-7 are shown in Figure 2.

[0080]

[0081] As shown in the table above, when "1.62% SLS" was used as a solubilizer (Example 4), an increase in initial dissolution was observed compared to when "0.79% SLS and 2.63% Poloxamer 407" was used (Example 5) or the "surfactant-free" example. However, in Example 4, the increase in dissolution rate was not significant, even though the SLS content was increased by 2.05 times compared to Example 5.

[0082] In addition, the tablets according to the present invention showed a faster dissolution rate than the capsule formulations of Comparative Examples 1-4. Considering that capsule formulations are generally formulations showing a faster dissolution rate than tablets, it was thought that containing D-mannitol and microcrystalline cellulose as diluents provided an improved dissolution rate compared to formulations containing lactose monohydrate (e.g., Tablettose 80). Even in the same capsule formulation, the dissolution rate was relatively significantly increased in Comparative Examples 1-2 containing SLS compared to Comparative Examples 3-4 not containing SLS, but there was no significant difference in the dissolution rate when containing 1% SLS and 2% SLS, suggesting that the critical micelle concentration of SLS is 1% or less.

[0083] When magnesium oxide (MgO) was used (Example 7), an excellent dissolution rate of 82.7% was observed in 10 minutes, but when the target hardness of 7 to 9 KP was compressed into a tablet, the target hardness was not reached, and the appearance changed to a bluish gray color during the short period between mixing and compression. Other dosage forms had no problems with tableting. Moreover, in a compatibility study of Crisdesalazine:MgO (1:1), when the stability was evaluated under long-term storage conditions (25℃ / 60% relative humidity) or accelerated conditions (40℃ / 60% relative humidity) in a closed state for 13 weeks in a transparent glass vial, or in a closed state for 7 weeks followed by an open state for 6 weeks, all mixtures showed an incompatible appearance change of turning gray, so although the dissolution was good, the dosage form was not considered further.

[0084]

[0085] Comparative evaluation of the safety of various prescriptions

[0086] The formulations were prepared using methods similar to those in the previous examples or comparative examples, and their long-term storage stability was evaluated. The formulations for each formulation were as shown in the table below.

[0087]

[0088]

[0089] The results of the long-term stability evaluation under conditions of 25±2 ℃ and 60±5% relative humidity are shown in the table below.

[0090]

[0091] N / A: Not Applied; % is the average of n=3 per formulation

[0092] As can be seen from the results in the above table, the percentages of maximum unknown (individual) associated substances and total associated substances were significantly reduced by including d-mannitol and MCC instead of lactose monohydrate as diluents. Crisdesalazine-100 mg tablets (Batch#C20003) and Crisdesalazine-200 mg tablets (Batch#C20004) provided in the present invention were very stable with little difference in the percentages of maximum unknown associated substances and total associated substances from the time of initial shipment to the subsequent 36 months (Table 11). That is, the percentage of maximum unknown substances in Crisdesalazine-100 mg tablets (Batch#C20003) and Crisdesalazine-200 mg tablets (Batch#C20004) was 0.02% on average at the time of shipment, but was 0.04% on average after 36 months, and the percentage of total unknown substances was 0.2% on average at the time of shipment, but was 0.2% after 36 months, which was very stable (Table 11).

[0093] In addition, in a long-term stability test on pilot batches of Crisdesalazine-100 mg tablets (Batch#C20003) and Crisdesalazine-200 mg tablets (Batch#C20004), they were very stable with no difference in the percentage of maximum unknown associated substances and total associated substances from the time of shipment to 36 months thereafter (results not provided in Table 11 above). That is, in the pilot tablets (Table 3, composition of Example 1; n=3) of Crisdesalazine-100 mg tablets (Batch#C20003), the percentages of maximum unknown associated substances were all at the BLOQ (<0.08%) level at the time of shipment, but were all at the BLOD (<0.025%) level even after 36 months, and the percentages of total associated substances were 0.24%, 0.20%, and 0.20% (average 0.21%) at the time of shipment, but were 0.10%, 0.11%, and 0.12% (average 0.11%) even after 36 months, which were very stable. In the pilot tablets of Crisdesalazine-200 mg tablets (Batch#C20004) (Table 3, composition of Example 2; n=3), the percentages of maximum unknown associated substances were all at the BLOQ (<0.08%) level at the time of shipment, but were all at the BLOD (<0.025%) level after 36 months. The percentages of total associated substances were 0.24%, 0.17%, and 0.22% (average 0.21%) at the time of shipment, but were 0.10%, 0.10%, and 0.11% (average 0.10%) after 36 months, showing great stability. In the pilot tablets (n=3) of the Crisdesalazine-50 mg tablets (Table 3, composition of Example 3) provided in the present invention, the percentages of maximum unknown associated substances were all at the BLOQ (<0.08%) level at the time of shipment, but were all at the BLOQ (<0.08%) level even after 36 months, and the percentages of total associated substances were 0.25%, 0.21%, and 0.21% (average 0.22%) at the time of shipment, but were 0.23%, 0.22%, and 0.23% (average 0.23%) even after 36 months, which were also very stable (results not provided in Table 11 above).

[0094] There was no dose-dependent increase in the amount of soluble substances among the three doses of Crisdesalazine tablets (50 mg, 100 mg, and 200 mg), probably because the proportions of each component in the formulations for the two doses were identical.

[0095] In contrast, other formulations, namely, 1) "Formulation containing high proportion (77.83%) of lactose monohydrate but not 1% SLS (Batch #GPGF-1601)", 2) "Formulation containing medium proportion (60.17%) of lactose monohydrate and 1% SLS (Batch #GPGO-1601; WO2020136441A1, claim 5 has the same composition as Batch #GPGO-1601)", 3) "Formulation containing low proportion (26.83%) of lactose monohydrate and 1% SLS (Batch #GPGT-1601)", showed worse stability than the compositions provided by the present invention. That is, compared to the initial shipment at 24 months, the maximum unknown flexible substance of formulations 1), 2), and 3) increased by 2 times (0.18%), 1.6 times (0.13%), and 2 times (0.14%), respectively, and the total flexible substance deteriorated by 2.0 times (0.61%), 1.4 times (0.46%), and 1.8 times (0.47%), respectively. However, after 30 months, the maximum unknown flexible substance of formulations 1), 2), and 3) was 1.03%, 0.59%, and 0.24%, respectively, which did not meet the passing standard (≤0.2%), and the total flexible substance was 1.27%, 0.74%, and 0.35%, respectively. 1) did not meet the passing standard (≤0.8%), while 2) and 3) barely met it.

[0096] Therefore, the novel formulations according to the present invention [formulations containing mannitol and microcrystalline cellulose instead of lactose monohydrate but containing 1% SLS (batch # C20003 & C20004)] provide formulations with improved long-term stability compared to previously published WO2020136441A1 claim 5 [formulations containing 1% SLS and 60.17% lactose monohydrate; batch # GPGT-1601] and unpublished formulations having different proportions of lactose monohydrate listed in the table above (batch # GPGF-1601, batch # GPGT-1601).

[0097] In the presence of 1% SLS, when the lactose monohydrate percentage decreased by 2.24-fold from 60.17% in the 100 mg capsules (batch # GPGO-1601) to 26.83% in the 200 mg capsules (batch # GPGO-1602), the maximum unknown associated matter and total associated matter at 30 months decreased by 2.46-fold and 2.11-fold, respectively. Therefore, the lactose monohydrate content is a major factor contributing to the decreased stability of Crisdesalazine even in the presence of 1% SLS.

[0098] The proportion of lactose monohydrate (77.8% of the total amount) in the 50 mg capsule (#GPGF-1601) decreased 1.29-fold (60.17% of the total amount) in the 100 mg capsule (#GPGO-1601) and 2.90-fold (26.8% of the total amount) in the 200 mg capsule (#GPGT-1601). However, in the 30-month stability test, the proportions of maximum unknown associated substances and total associated substances decreased 1.75-fold and 1.72-fold, respectively, in the 100 mg capsule (batch #GPGO-1601) compared to the 50 mg capsule (batch #GPGF-1601), and further decreased 4.29-fold and 3.62-fold, respectively, in the 200 mg capsule (batch #GPGT-1601). These results suggest that lactose content significantly affects the stability of Crisdesalazine formulations. Furthermore, the magnitude of the decrease in final soluble solids in both the 100 mg capsules (batch no. GPGO-1601) and 200 mg capsules (batch no. GPGT-1601) was greater than the decrease in lactose monohydrate content, suggesting that the 1% SLS content contributes to the stability of both the 100 mg and 200 mg capsules.

[0099] Based on the maximum unknown associated substances profile obtained from the 3-month accelerated stability test results and the 36-month actual long-term storage stability test results of the formulation based on “D-mannitol and microcrystalline cellulose” provided previously, the maximum unknown associated substances standard for the finished drug product can be strictly maintained at ≤0.15%.

[0100]

[0101] Evaluation of the influence of anionic surfactants with HLB exceeding 8 on the dissolution rate

[0102] A formulation similar to Comparative Examples 1 and 2 was prepared by varying only the amounts of the active ingredient and SLS, and the dissolution rate was evaluated at 15 minutes. The results are shown in the table below.

[0103]

[0104] As shown in the results in the table above, the presence or absence of SLS significantly affected the dissolution rate, and it was observed that SLS could improve the solubility of Crisdesalazine by increasing the intrinsic solubility of the substances within the formulation.

[0105]

[0106] Evaluation of the effect of cationic diluents on dissolution rates

[0107] Tablets were manufactured in a similar manner to Example 1 using the following prescription, and the dissolution rate was evaluated, and the results are shown in the table below.

[0108]

[0109] As shown in the table above, the B#011 and B#012 formulations containing dibasic calcium phosphate, a cationic diluent, showed significantly reduced dissolution rates and were also incompatible with Crisdesalazine.

Claims

1. A pharmaceutical composition comprising crisdesalazine or a pharmaceutically acceptable salt thereof as an active ingredient and a surfactant having an HLB (Hydrophilic and Lipophilic Balance) value of 8 or higher.

2. A pharmaceutical composition according to claim 1, wherein the surfactant is sodium lauryl sulfate, polmoxamer-407, or a mixture thereof.

3. A pharmaceutical composition according to claim 1 or 2, wherein the composition substantially does not contain lactose.

4. A pharmaceutical composition according to claim 3, wherein the composition comprises mannitol, microcrystalline cellulose or a mixture thereof as a diluent.

5. A pharmaceutical composition according to claim 1, wherein the composition comprises 5-70 wt% of Crisdesalazine or a pharmaceutically acceptable salt thereof, 5-80 wt% of mannitol, 5-80 wt% of microcrystalline cellulose, 2-10 wt% of a disintegrant, 0.1-10 wt% of sodium lauryl sulfate, and 0.1-10 wt% of a lubricant, based on the total weight of the composition.

6. In the fifth paragraph, the composition comprises 5-50 wt% of Crisdesalazine or a pharmaceutically acceptable salt thereof, 10-60 wt% of mannitol, 10-60 wt% of microcrystalline cellulose, 2-10 wt% of a disintegrant, 0.5-5 wt% of sodium lauryl sulfate, and 0.5-5 wt% of a lubricant, based on the total weight of the composition, and is a pharmaceutical composition in the form of a tablet.

7. A pharmaceutical composition according to claim 5 or 6, wherein the disintegrant is croscarmellose sodium.

8. A pharmaceutical composition according to claim 5 or 6, wherein the lubricant is sodium stearyl fumarate.

9. A pharmaceutical composition according to claim 1, wherein the composition has a pH of less than 7 when dispersed in 250 mL of purified water.

10. A pharmaceutical composition according to claim 9, wherein the composition comprises an acidifying agent.

11. A pharmaceutical composition according to claim 10, wherein the acidifying agent is fumaric acid, succinic acid, tartaric acid, or a mixture thereof.

Citation Information

Patent Citations

  • Pharmaceutical composition for treating or preventing degenerative and inflammatory diseases

    US8455470B2

  • Compounds, compositions and methods for preventing neurodegeneration in acute and chronic injuries in the central nervous system

    WO2001079153A1

  • Pharmaceutical composition for treating or preventing degenerative and inflammatory diseases

    WO2007119973A1

  • Medical use of 5-benzylaminosalicylic acid derivatives or salts thereof

    WO2010090494A2

  • Compositions and methods for treating neurodegenerative disorders

    WO2020136441A1